SAN LUIS OBISPO, California – June 27, 2003 – FzioMed, Inc. announced today the presentation of preclinical data showing the inhibition of post-surgical adhesion reformation using the company’s site-specific Oxiplex® gel. The poster presentation was made at the SEGI World Meeting on Minimally Invasive Surgery in Gynecology held in Rome, Italy from June 24 to June 28, 2003.
The Oxiplex gel is a bioabsorbable adhesion barrier being developed by FzioMed to reduce post-surgical adhesions in pelvic surgery. The product has achieved CE Mark approval in the European Union and is currently undergoing clinical evaluation in the United States.
The poster details studies using Oxiplex in a rabbit animal model of adhesion reformation, where adhesions are lysed and allowed to reform. Oxiplex gel demonstrated a significant reduction in the area of adhesion reformation compared with surgical controls. Examination of Oxiplex-treated sites further showed that the use of Oxiplex gel was associated with normal repair of the surgical site and there was no indication of inflammation at any of the surgical sites of adhesion reformation.
FzioMed is a privately held biomedical company engaged in the development and commercialization of advanced, absorbable biosurgery products based on the company’s patented Oxiplex platform technology. Oxiplex is an innovative polymer material that is formulated for a variety of surgical indications and markets. Products include those for the prevention of post-surgical adhesions, drug delivery and hemostasis. FzioMed products are at various stages of clinical and pre-clinical development, and commercialization, and are directed towards high growth markets in the rapidly growing field of biosurgery.
FzioMed® and Oxiplex® are registered trademarks of FzioMed, Inc.